{"id":390291,"date":"2019-12-30T00:00:00","date_gmt":"2019-12-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/bioeim0003-2020-biopharma-biosimilars-emerging-biosimilars-immunology-adalimumab-germany-wave-3-2019\/"},"modified":"2026-03-31T10:45:48","modified_gmt":"2026-03-31T10:45:48","slug":"bioeim0003-2020-biopharma-biosimilars-emerging-biosimilars-immunology-adalimumab-germany-wave-3-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/bioeim0003-2020-biopharma-biosimilars-emerging-biosimilars-immunology-adalimumab-germany-wave-3-2019\/","title":{"rendered":"Biosimilars | Emerging Biosimilars | Immunology | Adalimumab | Germany | Wave 3 | 2019"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>With the launch of five\u00a0adalimumab biosimilars into the European market since\u00a0October 2018\u2014Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), Hyrimoz (Sandoz), and Idacio\u00a0(Fresenius Kabi)\u2014competition within the already dynamic autoimmune therapy market will only increase. The first biosimilars to launch in this therapy area (infliximab [2015] and Benepali [2016]) have now been available for several years in Europe, and their uptake has been robust. With more adalimumab biosimilars forecast to launch in Europe over the next years, it will be critical for stakeholders active in the immune space to understand the dynamics of how adalimumab biosimilars will affect the uptake of the reference brand, Humira (AbbVie), and other originator biologics. Along with physician familiarity, awareness\u00a0and perceptions of biosimilars in general, and the launch of\u00a0adalimumab biosimilars in particular, we explore the drivers of and barriers to the uptake of adalimumab biosimilars in Germany. We discuss promotional efforts, as well as prescriber and nonprescriber profiles, and benchmark the agents against other available biosimilars to better understand the dynamics of the German biosimilar market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>Are German physicians aware of Amgevita, Imraldi, Hulio, Hyrimoz, and Idacio?<\/li>\n<li>What is driving and will drive the uptake of adalimumab biosimilars in Germany? What is the current level of use of Amgevita, Imraldi, Hulio, Hyrimoz, and Idacio, and how will this use change over time?<\/li>\n<li>Have German physicians experienced pressure to prescribe Amgevita, Imraldi, Hulio, Hyrimoz, and\/or Idacio to patients?<\/li>\n<li>What promotional messages are sales representatives using with the reference brand Humira and the adalimumab biosimilars Amgevita, Imraldi, Hulio, Hyrimoz, and Idacio?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Emerging Biosimilars<\/em> is a three-wave series based on primary research data collected at one, six, and twelve months postcommercial launch. The research captures physicians\u2019 awareness, perceptions, and use of biosimilars, as well as their impact on current therapies and anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.<\/p>\n<p><strong>RELEASE DATE<\/strong><\/p>\n<p>Wave 1: February 2019<\/p>\n<p>Wave 2: July 2019<\/p>\n<p>Wave 3: January\u00a02020<\/p>\n<p><strong>GEOGRAPHY<\/strong><\/p>\n<p>Germany<\/p>\n<p><strong>PRIMARY RESEARCH<\/strong><\/p>\n<p>Survey of 30 rheumatologists, 30 gastroenterologists, and 30 dermatologists<\/p>\n<p><strong>Key metrics included<\/strong><\/p>\n<ul>\n<li>Unaided and aided awareness of Amgevita, Imraldi, Hulio, Hyrimoz, and Idacio<\/li>\n<li>Familiarity with and impressions of Amgevita, Imraldi, Hulio, Hyrimoz, and Idacio<\/li>\n<li>Prescriber and nonprescriber profiles<\/li>\n<li>Willingness to prescribe Amgevita, Imraldi, Hulio, Hyrimoz, and Idacio<\/li>\n<li>Performance of Amgevita, Imraldi, Hulio, Hyrimoz, and Idacio on key attributes<\/li>\n<li>Sales representative frequency, reach, and satisfaction<\/li>\n<li>Benchmarking against previously launched biosimilars<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390291","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-geography-germany","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390291\/revisions"}],"predecessor-version":[{"id":393416,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390291\/revisions\/393416"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}